How Pharmacogenomics Testing Reduces Polypharmacy Risks with Dr. Houda Hachad Aranscia

Dr. Houda Hachad, Vice President of Clinical Operations at Aranscia, highlights the importance of regular medication reviews in an age of growing polypharmacy and advancements in the use of pharmacogenomics to identify potential risks. The key goal is to use the minimal effective dose of a medication and determine which drugs are most effective for treating identified conditions without causing unintended side effects. Adopting a preemptive pharmacogenomic testing approach for patients taking more than 5 drugs is noted as a way to reduce hospital readmissions, emergency room visits, and adverse drug events. Houda explains, "So polypharmacy is becoming more and more common. I think the data shows that up to 40% of adults now take a lot of medications. And polypharmacy is typically defined as the regular use of five medications or more. But in some settings, we're seeing what we call excessive polypharmacy, which is using nine or more." "So there are multiple patient cohorts, as you can imagine, that take these medications, definitely patients in hospital settings, older patients, patients that suffer from behavioral health issues, and any chronic conditions, patients with diabetes, hypertension, and obesity are going to be your typical polypharmacy patients. So our tools, which span genetic testing, medication reviews, and the use of various patient information to provide precision care, allow us to simplify and help doctors mitigate the risks associated with polypharmacy."   "Each time you add a medication to a patient, you're increasing the risk of having these adverse drug events. We have tools that can reduce the risk of polypharmacy, including pharmacogenomics." #Aranscia #Polypharmacy, #DrugGeneInteractions #dpydTesting #MedicationSafety #Pharmacogenomics  aranscia.com Download the transcript here